BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Amazon Secures 200 MW Wind Power Deals in Sweden 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Add as a preferred source on Google
WARREN, N.J., April 03, 2018 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place April 8-10, 2018, in Monte Carlo, Monaco.
Bellerophon Presentation Details
Date: Tuesday, April 10, 2018
Time: 10:15 AM Central European Summer Time/4:15 AM Eastern Time
Location: Monte Carlo, Monaco - Le Meridien Beach Plaza Hotel
The presentation will be webcast live and archived for 90 days on Bellerophon's Investor Relations website at investors.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of PAH, for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact
Bellerophon Therapeutics:
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4767
LifeSci Advisors
Brian Ritchie
212-915-2578
[email protected]
